Table 2.

Hazard ratios (HRs) with 95% confidence intervals (CI) of disease-specific and overall mortality of pancreatic ductal adenocarcinoma patients with low (0–1), moderate (2), and high (3–4) immune reaction based on immune cell score. Results based on whole sections and hotspots are presented separately

	Number of patients	Immune cell score 0–1 HR (95% CI)	Immune cell score 2 HR (95% CI)	Immune cell score 3–4 HR (95% CI)
Whole sections
Disease-specific mortality
All patients (crude)	79	1.00 (Reference)	0.48 (0.25–0.92)	0.41 (0.18–0.94)
All patients (adjusted)*	79	1.00 (Reference)	0.45 (0.21–0.95)	0.22 (0.08–0.60)
Overall mortality
All patients (crude)	79	1.00 (Reference)	0.47 (0.25–0.89)	0.51 (0.24–1.07)
All patients (adjusted)*	79	1.00 (Reference)	0.42 (0.20–0.88)	0.27 (0.11–0.67)
Hotspots
Disease-specific mortality
All patients (crude)	79	1.00 (Reference)	0.92 (0.48–1.77)	0.45 (0.20–1.03)
All patients (adjusted)*	79	1.00 (Reference)	1.10 (0.52–2.34)	0.64 (0.26–1.58)
Overall mortality
All patients (crude)	79	1.00 (Reference)	1.06 (0.57–1.98)	0.52 (0.24–1.13)
All patients (adjusted)*	79	1.00 (Reference)	1.41 (0.69–2.89)	0.70 (0.30–1.66)

*Adjusted for sex, age, tumour stage (TNM 8th edition), grade of differentiation, perineural invasion, radicality of resection (R0/R1)